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Abstract
Background: Hybrid positron emission tomography and magnetic resonance imaging (PET/MRI) scanners are
increasingly used for both clinical and preclinical imaging. Especially functional MRI sequences such as diffusion-
weighted imaging (DWI) are of great interest as they provide information on a molecular level, thus, can be used as
surrogate biomarkers. Due to technical restrictions, MR sequences need to be adapted for each system to perform
reliable imaging. There is, to our knowledge, no suitable DWI protocol for 1 Tesla PET/MRI scanners. We aimed to
establish such DWI protocol with focus on the choice of b values, suitable for longitudinal monitoring of tumor
characteristics in a rat liver tumor model.
Material and methods: DWI was first performed in 18 healthy rat livers using the scanner-dependent maximum of
4 b values (0, 100, 200, 300 s/mm2). Apparent diffusion coefficients (ADC) were calculated from different b value
combinations and compared to the reference measurement with four b values. T2-weighted MRI and optimized
DWI with best agreement between accuracy, scanning time, and system performance stability were used to monitor
orthotopic hepatocellular carcinomas (HCC) in five rats of which three underwent additional 2-deoxy-2-(18F)fluoro-D-
glucose(FDG)-PET imaging. ADCs were calculated for the tumor and the surrounding liver parenchyma and verified by
histopathological analysis.
Results: Compared to the reference measurements, the combination b = 0, 200, 300 s/mm2 showed the highest
correlation coefficient (rs = 0.92) and agreement while reducing the acquisition time. However, measurements with less
than four b values yielded significantly higher ADCs (p < 0.001). When monitoring the HCC, an expected drop of the
ADC was observed over time. These findings were paralleled by FDG-PET showing both an increase in tumor size and
uptake heterogeneity. Interestingly, surrounding liver parenchyma also showed a change in ADC values revealing
varying levels of inflammation by immunohistochemistry.
Conclusion: We established a respiratory-gated DWI protocol for a preclinical 1 T PET/MRI scanner allowing to monitor
growth-related changes in ADC values of orthotopic HCC liver tumors. By monitoring the changes in tumor ADCs over
time, different cellular stages were described. However, each study needs to adapt the protocol further according to
their question to generate best possible results.
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Introduction
Providing information on a molecular level, diffusion-
weighted magnetic resonance imaging (DWI) has been
proven to be a useful parameter for the differentiation
between healthy and pathologically altered tissue. In fact,
DWI has been used for tumor tissue characterization
and early assessment of tumor therapy response since
almost two decades in preclinical and clinical studies
[1–7] (reviewed in [8]). DWI is also sensitive to inflam-
matory processes, e.g., in the lung [9], intestine [10], and
liver [11].
DWI is a quantitative imaging technique that allows
the measurement of thermally driven molecular move-
ment of water, also known as Brownian motion. While
water molecules move freely in pure water, the magni-
tude of the range of motion in body tissues depends on
its composition, i.e., cell density and extracellular matrix,
and so reflects the characteristics of tissue types
(reviewed in [12]). At a steady state, the apparent diffu-
sion coefficient (ADC) as a measure for DWI is approxi-
mately 3.0 mm2/s for pure water preheated to 37 °C
[13]. Stejskal and Tanner first introduced a way for
diffusion-sensitive magnetic resonance imaging (MRI) in
1965 [14] by adding two diffusion gradients to a com-
mon MRI sequence, such as spin-echo (SE) or echo-pla-
nar-imaging (EPI), to measure the signal attenuation
caused by the motion of a water molecule. For quantita-
tive analysis, DWI enables the calculation of the ADC,
which is mainly dependent on the combination of diffu-
sion weighting factors, the so-called b values. However,
the optimal magnitude and amount of b values remain
controversial as the available hardware [15], the organ of
interest [16–18], and the method of data analysis [19]
play a major role for this technique.
In preclinical research, much effort has been put into
the development of hybrid imaging devices such as the
nanoScan positron emission tomography/magnetic res-
onance imaging (PET/MRI) scanner (Mediso, Hungary).
The MRI part of this dedicated 1 Tesla (T) small ani-
mal imaging system is based on a permanent magnet
allowing to operate the scanner in a standard animal
research laboratory without the need of extra cooling
or shielding of the MR compound [20]. However, due
to technical restrictions of the 1 T field strength, im-
aging protocols and MRI sequences established for
higher field strength scanners cannot be simply trans-
ferred to this scanner, e.g., DWI is only available with
SE sequences that are limited to a maximum of four b
values with a maximum magnitude of 600 s/mm2
depending on the chosen parameters. For achieving
both reasonable imaging quality and reliable quantita-
tive data sets, functional MR imaging such as DWI
needs to be adapted and optimized for this device to
achieve sufficient and valid data while keeping scanner
performance and scan duration and, thus, duration of
anesthesia, at a reasonable level.
The aim of this study was to evaluate the feasibility of
DWI scanning with the Mediso stand-alone 1 T nanoS-
can PET/MRI equipped with a permanent magnet and
no additional cooling for longitudinal animal studies.
Because there is, to the best of our knowledge, no pub-
lished study proposing a protocol for DWI for this sys-
tem, we first established an imaging protocol for DWI in
the abdominal region for the liver in healthy rats, focus-
ing on the selection of b values for ADC calculation. In
a second step, we applied the optimized DWI protocol
in a pilot study to monitor biologic alterations of the
liver in a hepatocellular carcinoma (HCC) homograft




Native rat HCC cell line N1-S1 was purchased from the
American Type Culture Collection (ATCC). N1-S1 cells
were maintained in RPMI1640 medium supplemented
with 10% fetal calf serum and 1% penicillin/strepto-
mycin. Cell cultures were grown in roller bottles at 37 °
C in an atmosphere of room air supplemented with 5%
CO2. Medium was changed to antibiotic-free medium
48 h prior to in vivo cell inoculation.
Generation of the HCC tumor homograft
All animal experiments were performed in accordance
with national and local guidelines for animal welfare and
were approved by the animal ethics committee of the
state Berlin (LAGeSo, Reg. No. G0059/14).
For in vivo experiments, Sprague-Dawley rats where
orthotopically inoculated into the liver with N1-S1 cells.
After achieving sufficient depth of anesthesia by Isoflur-
ane and low dose of Ketamine (10 mg/kg), a small me-
dian laparotomy was performed, and the left lateral liver
lobe was exposed. Cells were injected at a very slow rate
by visualization directly under the hepatic capsule. Suc-
cessful inoculation was verified by a pale, whitish area
around the point of injection underneath the hepatic
capsule. Animals were maintained under pathogen-free
conditions in a 12-h day and night cycle and were fed
with sterile food and water ad libitum. Rats were
weight-monitored during the in vivo experiments at least
once a week.
Phantom study
To pre-validate DWI by a phantom study, three water
phantoms were included in the analysis: one was filled
with 2 ml pure water, the others with 5% and 10% agar-
ose in 2 ml water, respectively. All phantoms were pre-
heated to 37 °C and temperature maintained by placing
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them on the heated animal bed. DWI was carried out
using b = 0, 200, 400, 600 s/mm2 and b = 0, 100, 200,
300 s/mm2 with no respiratory gating resulting in an ac-
quisition time of approximately 5 min.
In vivo imaging
Imaging was performed on a small animal 1 T PET/MRI
(nanoScan PET/MRI, Mediso, Hungary) equipped with a
1 T permanent magnet and a gradient coil providing
amplitudes up to 450 mT/m. A dedicated rat whole-
body coil was used for RF-transmission and signal re-
ceiving. Rats were anesthetized with general anesthesia
(1–2% isoflurane—3% for initiation—with oxygen at a
flow rate of approximately 0.5 l/min). Body temperature
was maintained at 37 °C during the time of imaging by
using a heated bed aperture. A pressure-sensitive pad
was placed under the thorax and used for respiratory
monitoring and gating.
DWI of the healthy liver was performed in healthy
Sprague-Dawley rats (n = 18). An axial T1 2D SE se-
quence was acquired for correct anatomical delineation
of the liver. DWI was carried out using an SE sequence
with respiratory gating with the following parameters:
TR = 362–560 ms; TE = 14.6 ms; slice thickness/gap =
1.3 mm/0.2 mm; matrix = 160 × 160 mm; diffusion
weighting direction = x, y, z; and number of excitations
= 1. b values were chosen due to the results of the phan-
tom studies: 4b = 0, 100, 200, 300 s/mm2. This resulted
in an acquisition time of 42 min at a respiratory rate of
40/min.
For tumor growth monitoring and DWI in HCC-bear-
ing rats (n = 5), animals were scanned before and at
three time points between days 10 and 20 after tumor
cell inoculation. For tumor delineation and volumetry, a
T2w 2D fast spin echo (FSE) sequence was established:
TR = 7500 ms; TE = 90 ms; slice thickness/gap = 1.3 mm/
0.2 mm; matrix = 258 × 228 mm; external averages = 5;
and number of excitations = 2. To visualize surrounding
liver parenchyma, a T1 3D gradient echo (GRE) sequence
was used: TR = 50 ms; TE = 2.3 ms; flip angle = 40°; slice
thickness/gap = 0.5 mm/0 mm; matrix = 160 × 160 mm;
and number of excitations = 2. DWI in HCC homograft
rats was performed under respiratory gating, and the
chosen b values (b = 0, 200, 300 s/mm2) resulted in a
mean acquisition time of 29 min at a respiratory rate of
40/min.
As a proof of concept, additional PET imaging was
performed in n = 3 HCC homograft rats to monitor glu-
cose metabolism during tumor growth at three time
points after inoculation of the tumor cells, i.e., after 10
and 20 days as well as either 13 or 16 days. Due to tracer
availability, one animal was imaged at two time points
only. FDG was injected intravenously (iv) into the rat tail
vein (0.2 ml; approximately 30 MBq) and scanned after
30 min to ensure tracer accumulation in the tumor tis-
sue (iterative image reconstruction, [ordered subset ex-
pectation maximization]; iterations, 6; subsets, 6; voxel
size, 500 × 500 × 600 μm3). Acquisition protocols in-
cluded a material map for attenuation and scatter cor-
rection during PET reconstruction. Prior to imaging, the
PET/MRI system was calibrated for FDG so that local
tissue concentrations in the tumor could be measured
quantitatively in kBq/ml tissue.
Image analysis: MRI
Image analysis was conducted with InterView Fusion
3.01 (Mediso, Hungary).
ADC maps were automatically calculated on a pixel by
pixel basis. The image pixel intensity depends on the b
value according to the following equation:
I ¼ I0e−bD
where D is the diffusion coefficient of tissues. The nat-
ural logarithms of the measured intensities are plotted
against the b values. The slope of the regression line rep-
resents the ADC.
For protocol establishment and optimization, ADC
values were calculated from the following b value combi-
nations: 4b (b = 0, 100, 200, 300 s/mm2), 3b1 (b = 0, 100,
200 s/mm2), 3b2 (b = 0, 200, 300 s/mm2), and 2b (b = 0,
300 s/mm2). These combinations were compared with
each other with regard to accuracy, stability of the scan-
ner performance, and acquisition time.
To correctly delineate liver parenchyma and tumor,
ADC maps were fused with T1 and T2 images, respect-
ively. For selection of healthy liver parenchyma, a region
of interest (ROI) was manually drawn onto four subse-
quent slices with the most liver parenchyma visible, i.e.,
slices directly adjacent to the recessus costodiaphragma-
ticus. In tumor-bearing animals, ROIs for ADC mapping
of the surrounding healthy liver parenchyma were placed
onto four subsequent slices around the largest diameter
of the tumor. The tumor ADC was calculated slice by
slice for the whole tumor. Slices showing strong motion
artifacts despite respiratory gating were excluded from
ADC calculation.
ADC maps from water and agarose phantoms were
generated from four subsequent slices.
Total tumor volumes were calculated based on T2-
weighted images by adding up all tumor-related voxels.
Image analysis: PET
Analysis was performed with dedicated software
(ROVER, version 3.0.34, ABX advanced biochemical
compounds GmbH, Radeberg, Germany). FDG-avid
tumor tissue (Volvital) was delineated with a unified fixed
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relative threshold at 45% of the maximum activity in
kBq/ml in the tumor without background adaptation
and defined as “viable.” If necessary, manual corrections
based on MRI were performed to exclude adjacent
non-tumorous FDG uptake in surrounding tissue. To
calculate the percentage of viable tumor tissue, the vol-
ume of the FDG-avid tumor tissue (PET: Volvital) as well
as the whole tumor volume (T2w: Voltumor) were deter-
mined. For correct delineation of the whole tumor, fused
FDG-PET/T2w images were used.
Histopathology of tumor surrounding liver parenchyma
Liver tissue surrounding the tumors (left liver lobe), as
well as healthy liver were snap frozen for immunohisto-
chemistry. Cryo sections (approx. 5 μm) from snap fro-
zen tissues were cut and air-dried overnight. For
histochemistry, sections were fixed with ice-cold aceton
p.a. and stained with hematoxylin and eosin (H&E). For
immunohistochemistry, sections were fixed in 4% for-
malin, dehydrated in ethanol, and air-dried prior to
heat-induced epitope retrieval. Sections were rinsed
with running tap water and incubated with antibodies
directed against CD3ε (Dako #IR50361–2), MPO (clone
MPO7, Dako), or CD163 (clone EPR19518, Abcam) at
room temperature. This was followed by incubation
with secondary antibodies (biotinylated donkey
anti-rabbit; Dianova). Biotin was detected by streptavi-
din conjugated with alkaline phosphatase, which con-
verted the substrate solution into dye deposits of
FastRed (both Dako). Primary antibodies were omitted
in negative control sections.
Stained sections were analyzed in a blinded fashion
using an AxioImager Z1 (ZEISS) and a Vectra3 (Perki-
nElmer) imager, respectively. For quantification of
positive cells or total hepatocytes in 10 high power
fields (field of vision with highest magnification; × 400
and × 200, respectively), inForm software (PerkinEl-
mer) was used.
Statistical analysis
Statistical analysis was conducted with IBM SPSS Statis-
tics version 24. Due to small sample size, normal distri-
bution was not assumed and in consequence data were
described using median, interquartile range (IQR), mini-
mum and maximum values, and depicted as boxplots.
Paired groups were compared using non-parametric
Wilcoxon test. All tests were two-sided and the level of
significance was set to p < 0.05. Calculations of the ADC
values using less b values (3b2, 3b1, 2b) were compared
to values calculated with the maximum of four b values
(4b = 0, 100, 200, 300 s/mm2) considered as the refer-
ence standard of this scanner. Correlations are shown
using spearman’s rank correlation coefficient. Agreement
of the different ADC calculation methods and scattering
was evaluated as described by Bland et al. [21].
Results
Phantom study
Phantom studies with 37 °C pre-heated water phantoms
revealed a mean ADC of 2.8 mm2/s for b = 0, 100, 200,
300 s/mm2 and 2.6 mm2/s for b = 0, 200, 400, 600 s/
mm2. As expected, agarose phantoms showed decreas-
ing ADC values with increasing agarose concentration
(Table 1).
DWI-protocol optimization
To establish a DWI protocol in areas of high respiratory
motion (liver and abdominal region) while keeping the
scanning time at a moderate level with respect to animal
anesthesia and animal throughput as well as long-term
scanner performance stability during a workday, b = 300
was chosen as the highest b value. DWI was first per-
formed in healthy rat livers using the maximum of four
b values (b = 0, 100, 200, 300 s/mm2) for this scanner as
the reference setting.
ADC values were then calculated for different b value
combinations (3b2 = 0, 200, 300 s/mm2; 2b = 0, 300 s/
mm2; 3b1 = 0, 100, 200 s/mm2) and statistically compared
to the 4b reference (4b = 0, 100, 200, 300 s/mm2). Abso-
lute ADC values of healthy liver parenchyma are shown in
Fig. 1 and Table 2. Combinations 3b1, 3b2, and 2b resulted
in significantly higher ADC values than those performed
with four b values (p3b2 < 0.001; p2b = 0.001; p3b1 < 0.001).
The median overestimation of ADC compared to 4b is cal-
culated with 0.015 × 10−3 mm2/s for 2b, 0.163 × 10−3 mm2/
s for 3b2, and 0.791 × 10−3 mm2/s for 3b1.
Correlation plots revealed high levels of correlation
between 4b and 3b2 (rs = 0.92; Fig. 2a) and 2b (rs = 0.88;
Fig. 2b), both correlations reaching statistical signifi-
cance (p < 0.001). The correlation of 4b and 3b1 was
clearly less distinct (rs = 0.44; Fig. 2c) and did not reach
the level of significance (p = 0.066).
Measurement with 3b2 resulted in a mean difference
of 0.18 × 10−3 mm2/s with 95% limits of agreement
0.0074 × 10−3 and 0.34 × 10−3 mm2/s. Hence, the range
between upper and lower limit of agreement amounted
Table 1 ADC values of 37 °C pre-heated water and water/
agarose phantoms
b value (s/mm2) Phantom ADC (mm2/s)
0, 100, 200, 300 Water 2.840
5% agarose 2.627
10% agarose 2.156
0, 200, 400, 600 Water 2.594
5% agarose 2.328
10% agarose 1.511
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to 0.33 × 10−3 mm2/s (Fig. 2d). Data acquired using 2b
showed the least mean difference of all three methods
with 0.11 × 10−3 mm2/s and 95% limits of agreement −
0.13 × 10−3 and 0.36 × 10−3 mm2/s (Fig. 2e). The range
here (0.49 × 10−3 mm2/s) slightly exceeded the previous
one. Considerably different values were measured with
3b1, i.e., a mean difference of 3.1 × 10−3 mm2/s with 95%
limits of agreement 2.3 × 10−3 and 4.0 × 10−3 mm2/s,
resulting in a range of 1.7 × 10−3 mm2/s (Fig. 2f ).
Based on the statistical analysis of b value combina-
tions, we selected the 3b2 approach as the best agree-
ment for performing DWI in the abdominal region
(liver) with respect to correlation of ADC values, dur-
ation of scanning time, and scanner stability.
Monitoring of HCC growth in rats
Anatomical imaging based on T2-weighted images
allowed a clear delineation of all tumors from the liver
parenchyma and revealed an increasing heterogeneity of
the tumor tissue during growth (Fig. 3b). Twenty days
after tumor inoculation, tumor volumes ranged between
1717 and 6754 mm3. For tumor growth monitoring, ani-
mals were analyzed individually and served as their own
control. One of the five tumors showed shrinkage by day
20 and was excluded from further image analysis. In
T2-weighted sequences, viable tumor tissue appears as a
hyperintense signal, while degraded tumor tissue results
in rather hypointense signals. During the initial moder-
ate growth phase until day 10 or 13, most tumors ap-
peared solid with low levels of necrosis. Once tumor
volumes expanded rapidly thereafter, the necrotic pro-
portion increased, while viable tissue decreased (Fig. 3b).
ADC values of the individual tumors showed a drop
during the initial growth in all homografts confirming
an increase in cellular density. When tumors exceeded
the size of 1500 mm3, ADC values remained on a plat-
eau (around 1.6 × 10−3 mm2/s; Fig. 4a). One rat was
measured only at two time points due to technical rea-
sons. Interestingly, the ADC of the tumor surrounding
liver parenchyma changed as well (Fig. 4b). During
tumor tissue establishment (up to day 10), ADC of the
liver parenchyma dropped clearly in all four homo-
grafted animals. When tumors increased in size, ADC of
most parenchymas showed a plateau, while in one rat
ADC values further decreased (Fig. 4b, parenchyma 2).
PET imaging revealed a decreasing percentage of the
FDG-avid tumor fraction over time during tumor growth
in all three animals (Fig. 3c and Table 3). All tumors
showed an increasingly heterogeneous FDG uptake. In
general, the center of the tumor did not accumulate
FDG, indicating necrotic or degraded tumor tissue, while
the tumor margin was still metabolically highly active
(Fig. 3d). Fused FDG-PET/T2w images as well as
threshold-based ROIs depicting viable tumor tissue are
shown in Fig. 3d.
Histopathology
Histomorphology of liver sections was evaluated by
H&E staining (Fig. 5a). Liver parenchyma of the native
rat displayed normal morphology with no signs of in-
flammation or neoplasia, while liver parenchymas sur-
rounding tumors showed varying levels of inflammation.
While surrounding parenchyma from rat 1 had no
inflammatory foci and showed only minimal inflamma-
tion in portal fields, the parenchyma surrounding the
tumor in rat 3 displayed many foci of inflammatory cells
that were partly necrotic, and all portal fields showed
mild to moderate inflammation. Parenchymas that
surrounded the tumors in rat 2 and 4 both showed com-
parable levels of inflammation of portal fields and num-
bers of inflammatory foci. Results are summarized in
Table 4 along with numbers of inflammatory CD3+ T
cells, CD163+ macrophages, and MPO+ neutrophils, and
Fig. 1 Boxplots of absolute ADC values calculated from different b
value combinations: 4b = 0, 100, 200, 300 s/mm2, 3b2 = 0, 200, 300 s/
mm2, 2b = 0, 300 s/mm2, and 3b1 = 0, 100, 200 s/mm2
Table 2 ADC values of healthy liver parenchyma in rats (n = 18)
calculated from different b value combinations
Method 4ba 3b2b 3b1c 2bd
ADC interquartile range (10–3 mm2/s) 0.39 0.44 0.58 0.52
ADC median (10–3 mm2/s) 2.69 2.79 3.48 2.81
ADC minimum (10–3 mm2/s) 2.23 2.42 2.83 2.28
ADC maximum (10–3 mm2/s) 3.16 3.40 5.75 3.37
a4b = 0, 100, 200, 300 s/mm2
b3b2 = 0, 200, 300 s/mm2
c3b1 = 0, 100, 200 s/mm2
d2b = 0, 300 s/mm2
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shown in Fig. 5 and Additional file 1: Figure S1. Tumor
histopathology also confirmed large areas of tumor ne-
crosis in accordance to tumor image characteristics
(Fig. 5).
In order to evaluate whether hepatocytes were com-
pressed by tumor growth or swollen due to injury or as
a stress reaction of the microenvironment to tumors
and/or inflammation, hepatocyte numbers were counted
in 10 high power fields (× 200 magnification) (Table 4).
While decreased numbers of hepatocytes indicate a cell
swelling, increased numbers show compressed tissue.
Discussion
Compared to strict anatomical MRI, DWI is considered
to provide functional information. The resulting ADC
values can be used to assess certain tissue characteris-
tics, in particular tissue cellularity, that can function as a
surrogate biomarker in the assessment of tumor therapy.
In this study, we established an optimized DWI proto-
col for the small animal nanoScan PET/MRI system
equipped with a 1 T permanent magnet with respect to
the known technical limitations. While initial DWI mea-
surements using four b values including the maximum
possible b value of 600 s/mm2 for this scanner resulted
in gradient instability, most likely due to an overheated
gradient system, we aimed for a robust sequence with
less b values. The most promising magnitude of b values
was identified in a phantom study and further tested to
monitor biologic alterations during tumor growth of
HCC lesions in a rat homograft tumor model.
A maximum b value of 300 s/mm2 finally used in this
study is considered as a very low value. While brain
DWI is usually performed with b values around 1000 s/
mm2, for abdomen and liver lower maximum b values of
500–800 s/mm2 [16, 17, 22] are recommended, as higher
values would increase the echo time (TE) as well as mo-
tion sensitivity and, thus, lower the signal-to-noise ratio
[23] in organs that are prone to motion artifacts such as
liver, e.g., due to respiration.
Technical limitations of the MRI hardware of the 1 T
nanoScan PET/MRI scanner include that a maximum of
four b values in the range of 0 to 600 s/mm2 is available
only. According to the phantom studies, the set of four
b values (4b = 0, 100, 200, 300 s/mm2) yielded the best
results for this scanner with respect to ADC values for
pure water published in literature. A disadvantage of this
setup, however, was the long scanning time of 42 min,
leading—in addition—to a decreased scanner stability
when several animals were imaged in a row. We also
noted that long scanning times resulted in overheating
of the gradient system. Therefore, different setups for
DWI were investigated focusing on shorter acquisition
times. The highest level of correlation and lowest scat-
tering was found for 3b2 (b = 0, 200, 300 s/mm2),
Fig. 2 a–c Correlation plots of measurements using 4b (b = 0, 100, 200, 300 s/mm2) plotted against a 3b2 (b = 0, 200, 300 s/mm2), b 3b1 (b =
0,100, 200 s/mm2), and c 2b (b = 0, 300 s/mm2). rs = spearman’s rank correlation coefficient. d–f Bland-Altman-Plots showing the differences
between ADC measurements plotted against their corresponding average with 95% limits of agreement (dotted lines)
Albrecht et al. EJNMMI Research            (2019) 9:21 Page 6 of 11
resulting in a mean scan duration of 29 min compared
to 42 min using the 4b set up. Using the 3b2 setup also
allowed stable DWI imaging all day long, using even
other sequences such as T1 and long T2w in between.
However, in comparison to the 4b setup, a mean over-
estimation of ADC values of 7% was observed with the
chosen parameters. Le Bihan et al. [24] described the in-
fluence of microcapillary blood flow when using low b
values, e.g., from 0 to about 100 s/mm2 [12, 25–27].
Hence, using b values > 150 s/mm2 [28, 29] is necessary
to avoid blood flow-corrupted ADC values.
In order to detect alterations in ADC values as an in-
dicator for changes in biological processes during longi-
tudinal studies, we considered the absolute ADC value
(represented by the median (Fig. 1)) of less importance
and focused rather on the precision of measurements
(represented by the IQR (Fig. 1) and range between the
95% limits of agreement (Fig. 2)), because large scatter
may mask minor changes in the values. Taken together,
we recommend using the 3b2 setup (b = 0, 200, 300 s/
mm2) for respiratory-gated DWI measurements in the
abdominal region as the best setup with respect to ac-
curacy, acquisition time, and performance stability of the
scanner.
As a proof of concept, we applied the established
DWI sequence for monitoring tumor growth in an
orthotopic HCC rat homograft tumor model. Once tu-
mors developed, an increasing cellular density of the
tumor was represented by decreasing ADC values.
The observed plateau of ADC values, once tumors
exceeded a size of approximately 1500 mm3, resulted
from balanced cell density and necrotic areas within
the tumors as seen on T2-weighted images (Fig. 3b)
and confirmed by histopathology (Fig. 5). These find-
ings were paralleled by PET results revealing an in-
creasingly heterogeneous FDG uptake in the growing
tumors and a drop of the FDG-avid fraction of the
tumor over time. Interestingly, the center of the tu-
mors did not accumulate FDG, indicating necrotic or
degraded tumor tissue, while the tumor margins were
still metabolically active which can be best observed
on fused FDG-PET/T2w images as well as by paramet-
ric threshold-based PET ROIs fused onto MR images.
These FDG patterns are well-known in fast growing
tumors where tumor growths is primarily limited to
the tumor margins while the center becomes
increasingly necrotic due to perfusion constraints. As
demonstrated by fused images, metabolically active
Fig. 3 a Rate of HCC growth in rats. Tumor volume was measured after 10 and 20 days, as well as 13 days for tumors 1 to 4 and 16 days for
tumor 5. b Representative T2-weighted images of rat 3 (tumor: white arrow) and rat 4 (tumor: white arrow) at three different time points
revealing morphologic heterogeneity due to a different tumor growth rate. Viable tumor tissue is represented by hyperintense areas within the
tumor, while degraded tumor tissue including necrotic areas is represented by hypointense areas. c The FDG-avid fractions of the tumor for three
rats are shown. Decreasing values indicate increasing non-metabolically active tissue. d Fused FDG-PET/T2w tumor images of rat 4 (upper row) as
well as threshold-based ROIs indicating viable tumor tissue for three different time points (d10, d16, d20)
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tumor areas on PET images can considerably differ
from the actual total tumor volume identified best by
T2w MRI. The sub-portion of non-metabolically active
tumor mass may be a mix of necrosis, cells undergoing
transition from metabolically active to inactive state,
and areas of both. By performing both FDG-PET and
anatomical and functional MRI, fused PET/MRI can
improve tumor texture analysis and contribute to fur-
ther characterization of tumor tissue providing differ-
ent biological information.
In addition to the changes of the tumor ADC values
measured over time, changes of the ADC values of the
tumor surrounding liver parenchyma were also ob-
served, indicating morphologic alterations of the liver
parenchyma during tumor growth. A possible explan-
ation for this observation is the interaction between
tumor cells and surrounding tissue as an immunologic
response. The observed decrease of the ADC values in-
dicates a reduction in free water motion, which may be
caused by infiltration of leucocytes, restricted sinusoids
or swelling of hepatocytes due to inflammatory pro-
cesses, all resulting in a reduction of the extracellular
water-filled space. Taouli et al. [11] previously described
lower ADC values in fibrotic and inflamed liver com-
pared to healthy liver tissue. DWI has also been sensi-
tive to inflammatory processes in other organs, e.g., in
the lungs [9] and intestine [10].
Histopathologic findings in our study revealed varying
levels of inflammation in the liver parenchyma of tumor
bearing rats. As histomorphology is better preserved in
formalin-fixed tissues, evaluation of H&E-stained cryo
sections was impaired, and thus, it was difficult to differ-
entiate between parenchymal changes caused by tumor
growth and inflammation and artifacts resulting from fix-
ation and histopathological processing. Therefore, we fo-
cused on an alternative but indirect method by counting
the hepatocytes in 10 high power fields (Table 1). While
lower numbers are indicative for swollen hepatocytes,
higher numbers indicate a compression of the liver paren-
chyma. Our results revealed varying numbers of hepato-
cytes but no consistent alterations in all animals. As
histopathology was only performed in single slices of each
specimen, the immunohistochemical analysis in our study
represents only a small snapshot of the total liver paren-
chyma surrounding the tumor. Therefore, further studies
with improved histopathological approaches to confirm ei-
ther inflammatory processes or other changes in the
microenvironment and extracellular matrix are necessary
to confirm and explain our observation of altered ADC
values in the liver tissue adjacent to HCC tumor lesions.
Conclusion
In conclusion, with respect to hardware restrictions of the
1 T nanoScan PET/MRI scanner, we established a feasible
and reliable DWI imaging protocol for this system allow-
ing to monitor biological changes in HCC liver tumors in
a rat homograft tumor model over time. Focusing on the
choice of b values for ADC calculation in the abdominal
region, the use of three b values (0, 200, 300 s/mm2)
Fig. 4 a ADC of the whole tumor as a function of the tumor volume.
Measurements were performed after 10, 13, and 20 days for tumors 1
to 3 and, due to technical reasons, after 10 and 16 days for tumor 4. b
ADC of the tumor surrounding liver parenchyma as a function of the
tumor volume. Time points were the same as in Fig. 4a
Table 3 Volumetry of FDG-PET in three tumor-bearing rats
Tumor Day Voltumor (mm
3) Volvital (mm
3) Viable tumor (%)
2 13 1532 1106 72
20 3821 2151 56
3 10 0143 130 90
16 1028 899 87
20 1929 1200 62
4 10 0898 900 100
16 3802 3090 81
20 9272 4066 44
Voltumor = volume of the whole tumor measured by MRI; Volvital = FDG-avid
tumor tissue defined as above a 45% threshold of the maximum tumor uptake
Albrecht et al. EJNMMI Research            (2019) 9:21 Page 8 of 11
delivered the best overall result when relevant parameters
such as accuracy of the measurement, scanning time, re-
spiratory gating, and performance stability of the system
were taken into account. The optimized respiratory-gated
DWI sequence presented here permitted high animal
throughput and allowed to monitor morphologic changes
during tumor growth, thus, proving the feasibility of DWI
using this preclinical hybrid PET/MR scanner. However,
each study needs to adapt the protocol according to their
question, i.e., region of interest and system, to generate
best possible results.
Furthermore, high-resolution anatomical MR imaging
plus DWI in combination with FDG-PET provides add-
itional and complementary information on tumor texture
because DWI and FDG measure different
patho-physiological aspects of tumor tissue. These differ-
ent parameters of fused multiparametric PET/MR images
may help to better characterize and understand tumor
heterogeneity and changes of the adjacent host tissue dur-
ing tumor growth in future research studies by providing
different aspects of biological information on a molecular
level within one imaging session.
Fig. 5 Hematoxylin and eosin (H&E) stained snap frozen tissue sections. a Native and tumor-bearing (rat 4) liver parenchyma. b Within tumor
tissue large areas are necrotic (white arrow)









Inflammatory foci (0.25 cm2) Hepatocytes (10 hpf)
Native 0 2525 25 27 12
Tumor 1 0 2029 47 56 35
Tumor 2 3 3139 33 11 14
Tumor 3 16 3051 28 74 442
Tumor 4 2 2513 28 35 38
aH&E: hematoxylin and eosin
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Additional file
Additional file 1: Immunohistochemic staining of liver parenchyma
from tumor-bearing rats 1–4 and one healthy rat. (DOCX 2697 kb)
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